112
Participants
Start Date
May 31, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
pramlintide acetate (Symlin)
subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
subcutaneous injection, dosing based on titration guidelines
basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
subcutaneous injection, dosing based on titration guidelines
Research Site, Northport
Research Site, Phoenix
Research Site, Loma Linda
Research Site, Aurora
Research Site, Hollywood
Research Site, Maitland
Research Site, Miami
Research Site, North Miami Beach
Research Site, Plantation
Research Site, Roswell
Research Site, Peoria
Research Site, Indianapolis
Research Site, Wichita
Research Site, Lexington
Research Site, Baton Rouge
Research Site, Baltimore
Research Site, Detroit
Research Site, Grand Rapids
Research Site, Jackson
Research Site, St Louis
Research Site, Butte
Research Site, Las Vegas
Research Site, Hamilton
Research Site, Albuquerque
Research Site, Albany
Research Site, Staten Island
Research Site, Mentor
Research Site, Portland
Research Site, Bridgeville
Research Site, Philadelphia
Research Site, Aiken
Research Site, Bartlett
Research Site, Nashville
Research Site, Austin
Research Site, Dallas
Research Site, Olympia
Research Site, Spokane
Lead Sponsor
AstraZeneca
INDUSTRY